Skip to NavigationSkip to content

Glenmark signs deal with Novartis over distribution in Brazil

Published on 24/06/19 at 10:45am

Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil.

Novartis will distribute three of Glenmark’s COPD drugs in Brazil from 1 July 2019.

The Swiss firm will be responsible for promoting, commercialising and distributing Glenmark's Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium) – all of which treat the symptoms of COPD.

“This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment,” said Glenn Saldanha, Chairman and Managing Director of Glenmark.

Glenmark receives around 5% of its revenue from Latin America. However Indian generic drugmakers – who are now facing pricing pressures in the US – are increasingly focused on increasing sales in big markets such as Brazil.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches